Proteome-wide Mendelian randomization and colocalization analyses have identified macrophage stimulating 1 (MST1) and (hepatocyte growth factor activator (HGFAC) as novel risk factors for IBD and UC, and warrant further investigation as potential therapeutic targets [63]. This evidence concerns the gene HGFAC and inflammatory bowel disease.